Interest in using GLP-1 drugs to reduce obesity combined with a desire by physicians to become less dependent on insurance-based reimbursement after the recent Change Healthcare cyberattack is building.
By eliminating the term "obesity" in favor of person-centric language, we pave the way for a more equitable healthcare system that prioritizes the well-being of all individuals, regardless of their size or shape.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Omada's newly expanded GLP-1 Care Track provides tailored exercise plans, support for getting off of GLP-1s and calorie tracking. It also offers insight into who is responding to GLP-1s and who is engaging in Omada's program.
A comprehensive approach to obesity management goes beyond prescribing medications for a quick fix.
The webinar, scheduled for March 6 at 2pm ET and sponsored by Build My Health, will discuss several topics related to weight management including: an overview of GLP-1 weight loss medication, automation in a subscription-based weight management program, and the rise of provider-to-consumer (PTC) models.
After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic conditions, and they will help the company meet projected demand for these products in years to come.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
How we discuss overweight and obese diagnoses and how we treat those patients is slowly starting to improve. However, there’s still a lot of work to be done – in how we manufacture, market, and manage life-changing weight care medications, as well as how we expand access and improve adherence to them.
WeightWatchers' new GLP-1 program offers daily nutritional and activity targets, recommended foods, recipes, food and activity tracking, a digital community, virtual workshops and access to coaches 24/7.
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.
Noom is now offering Noom Med to employers. The program is intended for patients who need more clinical support in their weight loss journey. It offers access to a clinician and medications, including GLP-1s.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Solera Health recently launched a program that aims to help patients who are interested in GLP-1s gain access to lifestyle change support. It also provides educational materials on GLP-1s.
Hello Alpha launched Ahead with Alpha, a weight management program for employers. It offers access to primary care providers trained in obesity care, medication management through weight loss drugs like GLP-1s, nutrition counseling with a registered dietitian and progress tracking.
Alfie Health's $2.1 million seed funding was led by Y Combinator and Nina Capital. It included participation from Goodwater Capital, Phoenix Investment Club and several angel investors.
Through LifeMD's new weight management program, consumers can gain access to GLP-1 prescriptions like Ozempic and Wegovy, clinical support, lab testing, education and more.
Found for Business is an evidence-based obesity care program that prescribes 13 different medications (including GLP-1s) in 60 different combinations. It combines the medication with support from providers, coaching and an app that offers meal and activity tracking.